Fincash » Mutual Funds India » Pharma Sector Shining in the Midst of Coronavirus
Table of Contents
Coronavirus has impacted the global Economy, due to which the domestic equity faced a huge decline. Most stocks have been hit low records. The BSE Sensex and NSE Nifty had their worst run since the 2nd week of March. On 18th March, Sensex ended at 28,896 points by falling 1709 points while Nifty failed below 8500 points.
In the midst of the mayhem, the pharma sector looks less affected as it is profiting handsomely. Investors hunting for safe havens in the ongoing turmoil can consider Investing in the pharma sector as it is showing an improving trend in Earnings.
In recent years, the pharmaceutical sector has augmented as the new listing of hospitals and diagnostic companies have been added more to the basket. The government policies and rising Income levels are giving robust growth in this sector.
The pharmaceutical sector was valued at US$33 billion in 2017. In 2018, the Indian pharmaceutical exports stood at US$17.27 billion and reached US$19.14 billion in 2019. The pharmaceutical Industry is anticipated to expand at a CAGR of 22.4% by 2020.
Indian companies received 304 Abbreviated New Drug Application from the US Food and Drug Administration in 2017. The pharma sector will expand and will reach US$55 billion by 2025.
The pharmaceuticals exports bulk drugs, intermediates, drug formulations, biologicals, herbal products and so on. India’s biotechnology industry compromising bio-agriculture, bio-industry, bio-pharmaceuticals and so on is expected to grow at the moderate rate of around 30% a year and it is expected to reach US$ 100 billion in the coming years.
The pharma sector provides several opportunities for investments and trade due to the following factors:
(Erstwhile SBI Pharma Fund) To provide the investors maximum growth opportunity through equity
investments in stocks of growth oriented sectors of the economy. SBI Healthcare Opportunities Fund is a Equity - Sectoral fund was launched on 31 Dec 04. It is a fund with High risk and has given a Below is the key information for SBI Healthcare Opportunities Fund Returns up to 1 year are on The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. Nippon India Pharma Fund is a Equity - Sectoral fund was launched on 5 Jun 04. It is a fund with High risk and has given a Below is the key information for Nippon India Pharma Fund Returns up to 1 year are on (Erstwhile UTI Pharma & Healthcare Fund) The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors. UTI Healthcare Fund is a Equity - Sectoral fund was launched on 28 Jun 99. It is a fund with High risk and has given a Below is the key information for UTI Healthcare Fund Returns up to 1 year are on Fund NAV Net Assets (Cr) 3 MO (%) 6 MO (%) 1 YR (%) 3 YR (%) 5 YR (%) 2023 (%) SBI Healthcare Opportunities Fund Growth ₹426.614
↓ -0.19 ₹3,628 -0.4 12.6 27.2 24 27.6 42.2 Nippon India Pharma Fund Growth ₹497.027
↓ -0.66 ₹8,915 -3.4 0.2 16 20.2 25.2 34 UTI Healthcare Fund Growth ₹278.669
↓ -0.79 ₹1,236 -3.3 5.5 26.3 20.9 25.3 42.9 Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 6 Feb 25 1. SBI Healthcare Opportunities Fund
CAGR/Annualized
return of 15.9% since its launch. Ranked 34 in Sectoral
category. Return for 2024 was 42.2% , 2023 was 38.2% and 2022 was -6% . SBI Healthcare Opportunities Fund
Growth Launch Date 31 Dec 04 NAV (06 Feb 25) ₹426.614 ↓ -0.19 (-0.04 %) Net Assets (Cr) ₹3,628 on 31 Dec 24 Category Equity - Sectoral AMC SBI Funds Management Private Limited Rating ☆☆ Risk High Expense Ratio 2.09 Sharpe Ratio 2.76 Information Ratio 0.52 Alpha Ratio 4.09 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-15 Days (0.5%),15 Days and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Jan 20 ₹10,000 31 Jan 21 ₹15,535 31 Jan 22 ₹17,594 31 Jan 23 ₹17,709 31 Jan 24 ₹26,160 31 Jan 25 ₹33,176 Returns for SBI Healthcare Opportunities Fund
absolute basis
& more than 1 year are on CAGR (Compound Annual Growth Rate)
basis. as on 6 Feb 25 Duration Returns 1 Month -2.4% 3 Month -0.4% 6 Month 12.6% 1 Year 27.2% 3 Year 24% 5 Year 27.6% 10 Year 15 Year Since launch 15.9% Historical performance (Yearly) on absolute basis
Year Returns 2023 42.2% 2022 38.2% 2021 -6% 2020 20.1% 2019 65.8% 2018 -0.5% 2017 -9.9% 2016 2.1% 2015 -14% 2014 27.1% Fund Manager information for SBI Healthcare Opportunities Fund
Name Since Tenure Tanmaya Desai 1 Jun 11 13.68 Yr. Pradeep Kesavan 31 Dec 23 1.09 Yr. Data below for SBI Healthcare Opportunities Fund as on 31 Dec 24
Equity Sector Allocation
Sector Value Health Care 90.04% Basic Materials 6.53% Asset Allocation
Asset Class Value Cash 3.35% Equity 96.57% Debt 0.08% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Dec 17 | SUNPHARMA13% ₹472 Cr 2,500,000 Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Mar 21 | MAXHEALTH6% ₹226 Cr 2,000,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB6% ₹220 Cr 360,000 Cipla Ltd (Healthcare)
Equity, Since 31 Aug 16 | 5000876% ₹214 Cr 1,400,000
↑ 120,000 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 23 | 5002575% ₹188 Cr 800,000 Lonza Group Ltd ADR (Healthcare)
Equity, Since 31 Jan 24 | LZAGY4% ₹151 Cr 300,000 Mankind Pharma Ltd (Healthcare)
Equity, Since 30 Apr 23 | MANKIND4% ₹151 Cr 523,016
↑ 123,016 Poly Medicure Ltd (Healthcare)
Equity, Since 31 Aug 24 | POLYMED4% ₹131 Cr 500,000 Krishna Institute of Medical Sciences Ltd (Healthcare)
Equity, Since 30 Nov 22 | 5433083% ₹126 Cr 2,100,000
↓ -100,000 Jupiter Life Line Hospitals Ltd (Healthcare)
Equity, Since 31 Aug 23 | JLHL3% ₹125 Cr 800,000
↓ -32,871 2. Nippon India Pharma Fund
CAGR/Annualized
return of 20.8% since its launch. Ranked 35 in Sectoral
category. Return for 2024 was 34% , 2023 was 39.2% and 2022 was -9.9% . Nippon India Pharma Fund
Growth Launch Date 5 Jun 04 NAV (07 Feb 25) ₹497.027 ↓ -0.66 (-0.13 %) Net Assets (Cr) ₹8,915 on 31 Dec 24 Category Equity - Sectoral AMC Nippon Life Asset Management Ltd. Rating ☆☆ Risk High Expense Ratio 1.88 Sharpe Ratio 2.01 Information Ratio -0.58 Alpha Ratio -3.65 Min Investment 5,000 Min SIP Investment 100 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Jan 20 ₹10,000 31 Jan 21 ₹15,604 31 Jan 22 ₹18,346 31 Jan 23 ₹17,643 31 Jan 24 ₹26,687 31 Jan 25 ₹30,762 Returns for Nippon India Pharma Fund
absolute basis
& more than 1 year are on CAGR (Compound Annual Growth Rate)
basis. as on 6 Feb 25 Duration Returns 1 Month -6.2% 3 Month -3.4% 6 Month 0.2% 1 Year 16% 3 Year 20.2% 5 Year 25.2% 10 Year 15 Year Since launch 20.8% Historical performance (Yearly) on absolute basis
Year Returns 2023 34% 2022 39.2% 2021 -9.9% 2020 23.9% 2019 66.4% 2018 1.7% 2017 3.6% 2016 7.6% 2015 -10.6% 2014 19.4% Fund Manager information for Nippon India Pharma Fund
Name Since Tenure Sailesh Raj Bhan 1 Apr 05 19.85 Yr. Kinjal Desai 25 May 18 6.7 Yr. Data below for Nippon India Pharma Fund as on 31 Dec 24
Equity Sector Allocation
Sector Value Health Care 98.14% Asset Allocation
Asset Class Value Cash 1.86% Equity 98.14% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA14% ₹1,237 Cr 6,556,349 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB9% ₹824 Cr 1,350,808 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 5002578% ₹755 Cr 3,203,676 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDY6% ₹508 Cr 3,662,170 Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 5000875% ₹474 Cr 3,100,000 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSP5% ₹473 Cr 648,795 Vijaya Diagnostic Centre Ltd (Healthcare)
Equity, Since 30 Sep 21 | 5433504% ₹320 Cr 3,025,298 Medplus Health Services Ltd (Healthcare)
Equity, Since 30 Nov 22 | 5434273% ₹296 Cr 3,564,680 Ajanta Pharma Ltd (Healthcare)
Equity, Since 30 Apr 22 | 5323313% ₹281 Cr 959,323 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND3% ₹267 Cr 1,500,000 3. UTI Healthcare Fund
CAGR/Annualized
return of 15.1% since its launch. Ranked 40 in Sectoral
category. Return for 2024 was 42.9% , 2023 was 38.2% and 2022 was -12.3% . UTI Healthcare Fund
Growth Launch Date 28 Jun 99 NAV (07 Feb 25) ₹278.669 ↓ -0.79 (-0.28 %) Net Assets (Cr) ₹1,236 on 31 Dec 24 Category Equity - Sectoral AMC UTI Asset Management Company Ltd Rating ☆ Risk High Expense Ratio 2.38 Sharpe Ratio 2.32 Information Ratio -0.22 Alpha Ratio -0.45 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Jan 20 ₹10,000 31 Jan 21 ₹15,455 31 Jan 22 ₹17,925 31 Jan 23 ₹16,531 31 Jan 24 ₹24,618 31 Jan 25 ₹30,793 Returns for UTI Healthcare Fund
absolute basis
& more than 1 year are on CAGR (Compound Annual Growth Rate)
basis. as on 6 Feb 25 Duration Returns 1 Month -5.4% 3 Month -3.3% 6 Month 5.5% 1 Year 26.3% 3 Year 20.9% 5 Year 25.3% 10 Year 15 Year Since launch 15.1% Historical performance (Yearly) on absolute basis
Year Returns 2023 42.9% 2022 38.2% 2021 -12.3% 2020 19.1% 2019 67.4% 2018 1.2% 2017 -7.5% 2016 6.2% 2015 -9.7% 2014 12.4% Fund Manager information for UTI Healthcare Fund
Name Since Tenure Kamal Gada 2 May 22 2.76 Yr. Data below for UTI Healthcare Fund as on 31 Dec 24
Equity Sector Allocation
Sector Value Health Care 96.03% Basic Materials 1.27% Financial Services 0.29% Asset Allocation
Asset Class Value Cash 2.41% Equity 97.59% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMA11% ₹137 Cr 725,000 Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | 5000876% ₹71 Cr 464,949
↑ 14,289 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | DRREDDY5% ₹65 Cr 470,234 Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | 5323315% ₹57 Cr 193,047 Glenmark Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Mar 24 | 5322964% ₹50 Cr 309,311 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND4% ₹47 Cr 266,306 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSP4% ₹44 Cr 60,000 Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Dec 20 | 5328433% ₹40 Cr 557,701
↓ -53,957 Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Dec 20 | PGHL3% ₹39 Cr 74,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB3% ₹37 Cr 61,480
Medical spending in India has projected to grow 9-12 per cent over the next five years. Further, the growth in domestic sales may increase because of coronavirus. To add more, in such a volatile phase, there are a few Mutual Funds that are performing well.
Speedy introduction of generic or new drugs into the market are in focus and it has expected to benefit the Indian Pharmaceutical companies.
You Might Also Like